Berger Financial Group Inc Sells 1,790 Shares of Pfizer Inc. $PFE

Berger Financial Group Inc reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.7% in the second quarter, HoldingsChannel reports. The firm owned 14,888 shares of the biopharmaceutical company’s stock after selling 1,790 shares during the period. Berger Financial Group Inc’s holdings in Pfizer were worth $361,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PFE. Capital Advisory Group Advisory Services LLC boosted its stake in Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 388 shares in the last quarter. Trust Co of the South grew its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 441 shares during the last quarter. Charter Oak Capital Management LLC increased its position in shares of Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after acquiring an additional 444 shares during the period. Ballentine Partners LLC raised its stake in Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after acquiring an additional 458 shares during the last quarter. Finally, Members Trust Co lifted its position in Pfizer by 2.1% during the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 467 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on PFE shares. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.45 on Tuesday. The firm has a market cap of $150.38 billion, a PE ratio of 14.07, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $24.72 and a 200 day moving average price of $24.12.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.